Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation of Lobaplatin Concurrent With IMRT for the Treatment of NPC: A Phase I Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. The pathological type is non keratinized carcinoma (according to the pathological classification of World, Health, Organization, WHO)~2. Overall Stage III-IVB (according to the seventh edition of AJCC staging system).~3. Age between 18-65 years old.~4. There is no evidence of distant metastasis.~5. Eastern Cooperative Oncology Group performance status 0 or 1.~6. Normal marrow function: white blood count \> 4 \* 109/L, hemoglobin \> 90g/L, and platelet count \> 100 \* 109/L.~7. Normal liver function: total bilirubin (TBIL) and alanine aminotransferase (ALT) \<2 times the normal values.~8. Normal renal function: creatinine (Cr) \<1.5 times the normal value.~9. The patient must be the basic content of this research and the defendant signed the informed consent.~Exclusion Criteria:~1. The pathological type is WHO squamous cell carcinoma or squamous cell carcinoma.~2. Age \> 65 years old, or \< 18 yeas old.~3. The purpose of treatment is palliative.~4. There was a history of malignancy, except for adequately treated basal cell carcinoma or squamous cell carcinoma, and carcinoma in situ of the cervix.~5. Women who are pregnant or lactating (for women of child-bearing age) should consider pregnancy tests; effective contraception should be emphasized during treatment）.~6. Previously received radiation therapy .~7. Primary and neck metastases were treated with chemotherapy or surgery.~8. Accompanied by other serious diseases may pose a greater risk or impact on test compliance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Experience group 1 (Type: EXPERIMENTAL): The dose of lobaplatin is 25mg/m2 on d1,d22,d43.
- Experience group 2 (Type: EXPERIMENTAL): The dose of lobaplatin is on d1,d22,d43.
- Experience group 3 (Type: EXPERIMENTAL): The dose of lobaplatin is on d1,d22,d43.
- Experience group 4 (Type: EXPERIMENTAL): The dose of lobaplatin is 40mg/m2 on d1,d22,d43.
- Experience group 5 (Type: EXPERIMENTAL): The dose of lobaplatin is 45mg/m2 on d1,d22,d43.
- Experience group 6 (Type: EXPERIMENTAL): The dose of lobaplatin is 50mg/m2 on d1,d22,d43.

Based on this trial design, predict the completion outcome and termination type (if applicable).